UK authorises Casgevy gene-editing therapy from age five for severe inherited blood disorders
On 29 October 2026 the UK's MHRA extended Casgevy authorisation to eligible children aged five and over with severe sickle-cell disease or transfusion-dependent beta-thalassaemia, down from 12. Regulatory authorisation is distinct from access and NHS funding.






